Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.

International journal of pharmaceutics - 15 Apr 2012

Aquino R P, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, Russo P

Abstract excerpt

The high hygroscopicity of gentamicin (G) as raw material hampers the production of respirable particles during aerosol generation and prevents its direct use as powder for inhalation in patients suffering from cystic fibrosis (CF). Therefore, this research aimed to design a new dry powder formulation of G studying dispersibility properties of an aminoacid, L-leucine (leu), and appropriate process conditions....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Inhalation
Share to Chemistry, Pharmaceutical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Stability

Share to Gentamicins

Share to Leucine

Share to Particle Size

Share to Respiratory Mucosa

Share to Solvents

Source

Identifiers

PMID: 22301426
DOI: 10.1016/j.ijpharm.2012.01.026

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.PMID 22301426Read ↗

Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory SystemSemantic proximity Read ↗

Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.Semantic proximity Read ↗

Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into OpportunitiesSemantic proximity Read ↗

Site-Specific Microparticle Inhalation Therapy: A New Approach to Nasopharyngeal SymptomsSemantic proximity Read ↗

Inhaled gene delivery: a formulation and delivery approachSemantic proximity Read ↗

MicroRNA nanocarriers for the treatment of chronic obstructive pulmonary diseaseSemantic proximity Read ↗

Computational Fluid Particle Dynamics (CFPD)-Based Virtual Next Generation Impactor (vNGI) to Predict the Aerodynamic Particle Size Distribution (APSD) of Respiratory Drug Delivery Products: Toward New Approach Methodologies (NAMs) in Inhaler Performance EvaluationSemantic proximity Read ↗

Personalized Inhaler Selection in COPD and Asthma: Clinical Implications of Aerosol Characteristics and Device PerformanceSemantic proximity Read ↗

Lung organoids and microplastic fibers: a new exposure model for emerging contaminantsSemantic proximity Read ↗

Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulationsSemantic proximity Read ↗

Computational Fluid Particle Dynamics-Informed Machine Learning Prototype for a User-Centered Smart Inhaler Enabling Uniform Drug Delivery to Small AirwaysSemantic proximity Read ↗

Is aggregated synthetic amorphous silica toxicologically relevant?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.